Mineralys Therapeutics, Inc.
MLYS
$42.16
$2.777.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.52% | 13.76% | 13.13% | -37.37% | -30.17% |
| Total Depreciation and Amortization | 6.67% | 0.00% | 36.36% | 22.22% | 12.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.58% | 44.63% | 320.84% | 1,608.00% | 107.86% |
| Change in Net Operating Assets | 282.77% | 70.12% | -444.68% | -47.22% | -14.55% |
| Cash from Operations | 33.68% | 31.95% | -33.19% | -66.48% | -57.51% |
| Capital Expenditure | -- | -- | 100.00% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 53.83% | -211.14% | 4.93% | 929.50% | 113.84% |
| Cash from Investing | 53.83% | -211.14% | 4.98% | 929.02% | 113.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.78% | 138,067.15% | 242.50% | -69.70% | -99.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -370.00% | 78.72% | -14.63% | 85.56% | -350.79% |
| Cash from Financing | -94.81% | 210,210.00% | 9,100.00% | 99.34% | -100.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -224.16% | 202.77% | -42.83% | 230.39% | -154.88% |